Role of androgen receptor signaling pathway-related lncRNAs in the prognosis and immune infiltration of breast cancer
Androgen receptor (AR) is strong association with breast cancer (BRCA). We aimed to investigate the effect of the androgen receptor signaling pathway-related long non-coding RNAs (ARSP-related lncRNAs) on the process of subtype classification and the tumor microenvironment (TME) of breast cancer (BR...
Saved in:
Published in | Scientific reports Vol. 12; no. 1; pp. 20631 - 17 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
30.11.2022
Nature Publishing Group Nature Portfolio |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Androgen receptor (AR) is strong association with breast cancer (BRCA). We aimed to investigate the effect of the androgen receptor signaling pathway-related long non-coding RNAs (ARSP-related lncRNAs) on the process of subtype classification and the tumor microenvironment (TME) of breast cancer (BRCA). Our study screen ARSP-related lncRNAs for the construction of a risk model. The single-sample gene set enrichment analysis (ssGSEA) method was used to detect the differences between the immune responses generated by the patients belonging to the low- and high-risk groups. The relationship between the ARSP-related lncRNAs and TME was explored following the process of cluster analysis. The univariate Cox analysis and the Lasso regression analysis method was used to screen nine of these lncRNAs to develop a risk model. It was observed that risk score could function as an independent prognostic factor, affecting the prognoses of patients suffering from BRCA. The validity of the model was assessed by analyzing the generated calibration curves and a nomogram. Additionally, the effect of the risk score on the extent of immune cell infiltration realized in TME was explored. M2 macrophages correlated positively, whereas NK cells, CD4+ T cells, and naive B cells correlated negatively with the risk score. Results obtained using the cluster analysis indicated that immune scores correlated with clustered subtypes. Finally, the risk score and cluster subtypes were analyzed to study the sensitivity of the patients toward different drugs to identify the appropriate therapeutic agents. The prognoses of patients suffering from BRCA can be accurately predicted by ARSP-related lncRNAs. |
---|---|
AbstractList | Abstract Androgen receptor (AR) is strong association with breast cancer (BRCA). We aimed to investigate the effect of the androgen receptor signaling pathway-related long non-coding RNAs (ARSP-related lncRNAs) on the process of subtype classification and the tumor microenvironment (TME) of breast cancer (BRCA). Our study screen ARSP-related lncRNAs for the construction of a risk model. The single-sample gene set enrichment analysis (ssGSEA) method was used to detect the differences between the immune responses generated by the patients belonging to the low- and high-risk groups. The relationship between the ARSP-related lncRNAs and TME was explored following the process of cluster analysis. The univariate Cox analysis and the Lasso regression analysis method was used to screen nine of these lncRNAs to develop a risk model. It was observed that risk score could function as an independent prognostic factor, affecting the prognoses of patients suffering from BRCA. The validity of the model was assessed by analyzing the generated calibration curves and a nomogram. Additionally, the effect of the risk score on the extent of immune cell infiltration realized in TME was explored. M2 macrophages correlated positively, whereas NK cells, CD4+ T cells, and naive B cells correlated negatively with the risk score. Results obtained using the cluster analysis indicated that immune scores correlated with clustered subtypes. Finally, the risk score and cluster subtypes were analyzed to study the sensitivity of the patients toward different drugs to identify the appropriate therapeutic agents. The prognoses of patients suffering from BRCA can be accurately predicted by ARSP-related lncRNAs. Androgen receptor (AR) is strong association with breast cancer (BRCA). We aimed to investigate the effect of the androgen receptor signaling pathway-related long non-coding RNAs (ARSP-related lncRNAs) on the process of subtype classification and the tumor microenvironment (TME) of breast cancer (BRCA). Our study screen ARSP-related lncRNAs for the construction of a risk model. The single-sample gene set enrichment analysis (ssGSEA) method was used to detect the differences between the immune responses generated by the patients belonging to the low- and high-risk groups. The relationship between the ARSP-related lncRNAs and TME was explored following the process of cluster analysis. The univariate Cox analysis and the Lasso regression analysis method was used to screen nine of these lncRNAs to develop a risk model. It was observed that risk score could function as an independent prognostic factor, affecting the prognoses of patients suffering from BRCA. The validity of the model was assessed by analyzing the generated calibration curves and a nomogram. Additionally, the effect of the risk score on the extent of immune cell infiltration realized in TME was explored. M2 macrophages correlated positively, whereas NK cells, CD4+ T cells, and naive B cells correlated negatively with the risk score. Results obtained using the cluster analysis indicated that immune scores correlated with clustered subtypes. Finally, the risk score and cluster subtypes were analyzed to study the sensitivity of the patients toward different drugs to identify the appropriate therapeutic agents. The prognoses of patients suffering from BRCA can be accurately predicted by ARSP-related lncRNAs. Androgen receptor (AR) is strong association with breast cancer (BRCA). We aimed to investigate the effect of the androgen receptor signaling pathway-related long non-coding RNAs (ARSP-related lncRNAs) on the process of subtype classification and the tumor microenvironment (TME) of breast cancer (BRCA). Our study screen ARSP-related lncRNAs for the construction of a risk model. The single-sample gene set enrichment analysis (ssGSEA) method was used to detect the differences between the immune responses generated by the patients belonging to the low- and high-risk groups. The relationship between the ARSP-related lncRNAs and TME was explored following the process of cluster analysis. The univariate Cox analysis and the Lasso regression analysis method was used to screen nine of these lncRNAs to develop a risk model. It was observed that risk score could function as an independent prognostic factor, affecting the prognoses of patients suffering from BRCA. The validity of the model was assessed by analyzing the generated calibration curves and a nomogram. Additionally, the effect of the risk score on the extent of immune cell infiltration realized in TME was explored. M2 macrophages correlated positively, whereas NK cells, CD4+ T cells, and naive B cells correlated negatively with the risk score. Results obtained using the cluster analysis indicated that immune scores correlated with clustered subtypes. Finally, the risk score and cluster subtypes were analyzed to study the sensitivity of the patients toward different drugs to identify the appropriate therapeutic agents. The prognoses of patients suffering from BRCA can be accurately predicted by ARSP-related lncRNAs.Androgen receptor (AR) is strong association with breast cancer (BRCA). We aimed to investigate the effect of the androgen receptor signaling pathway-related long non-coding RNAs (ARSP-related lncRNAs) on the process of subtype classification and the tumor microenvironment (TME) of breast cancer (BRCA). Our study screen ARSP-related lncRNAs for the construction of a risk model. The single-sample gene set enrichment analysis (ssGSEA) method was used to detect the differences between the immune responses generated by the patients belonging to the low- and high-risk groups. The relationship between the ARSP-related lncRNAs and TME was explored following the process of cluster analysis. The univariate Cox analysis and the Lasso regression analysis method was used to screen nine of these lncRNAs to develop a risk model. It was observed that risk score could function as an independent prognostic factor, affecting the prognoses of patients suffering from BRCA. The validity of the model was assessed by analyzing the generated calibration curves and a nomogram. Additionally, the effect of the risk score on the extent of immune cell infiltration realized in TME was explored. M2 macrophages correlated positively, whereas NK cells, CD4+ T cells, and naive B cells correlated negatively with the risk score. Results obtained using the cluster analysis indicated that immune scores correlated with clustered subtypes. Finally, the risk score and cluster subtypes were analyzed to study the sensitivity of the patients toward different drugs to identify the appropriate therapeutic agents. The prognoses of patients suffering from BRCA can be accurately predicted by ARSP-related lncRNAs. |
ArticleNumber | 20631 |
Author | Liu, Guowen Huang, Guo Cao, Hong Chen, Juan |
Author_xml | – sequence: 1 givenname: Guo surname: Huang fullname: Huang, Guo organization: Hengyang Medical School, University of South China, Key Laboratory of Tumor Cellular and Molecular Pathology, College of Hunan Province, Cancer Research Institute, University of South China, Department of Breast and Thyroid Surgery, Hengyang Medical School, The Second Affiliated Hospital, University of South China – sequence: 2 givenname: Hong surname: Cao fullname: Cao, Hong organization: Department of Breast and Thyroid Surgery, Hengyang Medical School, The Second Affiliated Hospital, University of South China – sequence: 3 givenname: Guowen surname: Liu fullname: Liu, Guowen email: liugw8318@163.com organization: Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital – sequence: 4 givenname: Juan surname: Chen fullname: Chen, Juan email: chenjuan@usc.edu.cn organization: Department of Radiotherapy, The Second Affiliated Hospital, Hengyang Medical School, University of South China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36450882$$D View this record in MEDLINE/PubMed |
BookMark | eNp9ks1vFCEYxiemxtbaf8CDIfHiZZTPAS4mTeNHk0aTRs-EgXdm2czCCjOa_veyu622PZQLBJ7nxwPv-7I5iilC07wm-D3BTH0onAitWkxpSwVlpMXPmhOKuWgpo_To3vq4OStljesQVHOiXzTHrOMCK0VPmuU6TYDSgGz0OY0QUQYH2zllVMIY7RTiiLZ2Xv2xN22Gyc7g0RTd9bfzgkJE8wrQthpjKqHsIChsNkuEejaEac52Dinu-H0GW2bkbHSQXzXPBzsVOLudT5ufnz_9uPjaXn3_cnlxftU6wfHcEoIl7wiTPcdCaS5lJ3qtvWOY9mBxNzgK3nlKtPCUD9YK7D3rKOGDUoyx0-bywPXJrs02h43NNybZYPYbKY_G5jm4CYwFrbzSEhym3InBEg9KivqLGijDqrI-Hljbpd_UWyHW100PoA9PYliZMf02WhLaSVkB724BOf1aoMxmE4qDabIR0lIMlZx3neSSVOnbR9J1WnKtxl5FNda62wHf3E_0L8pddatAHQQup1IyDMaFeV-RGjBMhmCz6yVz6CVTe8nse8ngaqWPrHf0J03sYCpVHEfI_2M_4foLvAHbsg |
CitedBy_id | crossref_primary_10_3389_fcell_2024_1403396 crossref_primary_10_3390_cancers16162920 crossref_primary_10_3389_fimmu_2023_1194300 crossref_primary_10_18632_aging_205946 crossref_primary_10_1016_j_heliyon_2024_e33930 crossref_primary_10_1016_j_ncrna_2024_01_014 crossref_primary_10_1080_10286020_2024_2390508 crossref_primary_10_3390_cancers16234043 crossref_primary_10_3892_ijo_2023_5595 crossref_primary_10_1002_tox_24205 |
Cites_doi | 10.1093/nar/gkaa970 10.1186/s12935-020-01472-9 10.3892/or.2021.8139 10.1038/nmeth.3337 10.3389/fgene.2021.748279 10.1016/j.bbcan.2018.05.004 10.1016/j.celrep.2019.12.011 10.1080/21655979.2021.1969833 10.1001/jamanetworkopen.2021.14904 10.1086/302366 10.1002/jcp.29847 10.1056/NEJMoa1701830 10.1097/med.0000000000000251 10.26355/eurrev_202004_20824 10.7150/jca.29670 10.1038/s41598-022-14897-1 10.1038/s41418-018-0123-6 10.1155/2021/6290261 10.1016/j.ajhg.2020.09.001 10.1016/j.biopha.2019.108718 10.3322/caac.21609 10.1155/2020/6827057 10.1159/000456910 10.2147/cmar.S322195 10.1007/s10549-009-0436-8 10.1186/bcr3599 10.1073/pnas.0506580102 10.3390/molecules25020358 10.1111/jcmm.14721 10.3389/fcell.2021.729965 10.1016/j.mce.2021.111324 10.1016/s1470-2045(14)70080-4 10.1093/jnci/djz208 10.1159/000499931 10.3389/fonc.2020.582863 10.1038/s41419-020-02856-5 10.1593/neo.08274 10.1016/j.ymeth.2017.06.010 10.1038/modpathol.2011.54 |
ContentType | Journal Article |
Copyright | The Author(s) 2022 2022. The Author(s). The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
DOI | 10.1038/s41598-022-25231-0 |
DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2045-2322 |
EndPage | 17 |
ExternalDocumentID | oai_doaj_org_article_ae98d897ec024c5fa1de8752049e2308 PMC9712677 36450882 10_1038_s41598_022_25231_0 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: The Guiding Project of Clinical Medical Technology Innovation in Hunan Province grantid: 2021SK51706 – fundername: The Scientific Research Program of Hunan Provincial Health Commission grantid: 20201969 – fundername: The Clinical Research Center for Breast & Thyroid Disease Prevention in Hunan Province grantid: 2018SK4001 – fundername: The Second People's Hospital of Shenzhen High-level Capital Project grantid: 4004009 – fundername: ; grantid: 2021SK51706 – fundername: ; grantid: 4004009 – fundername: ; grantid: 2018SK4001 – fundername: ; grantid: 20201969 |
GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFPKN CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7XB 8FK AARCD K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS Q9U 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c540t-110746137b4058947765b99dc302bea06fc2edcd2195d24faa50dd36214f88333 |
IEDL.DBID | M48 |
ISSN | 2045-2322 |
IngestDate | Wed Aug 27 01:13:54 EDT 2025 Thu Aug 21 18:38:47 EDT 2025 Mon Jul 21 10:46:17 EDT 2025 Wed Aug 13 07:38:39 EDT 2025 Thu Jan 02 22:52:58 EST 2025 Tue Jul 01 00:55:33 EDT 2025 Thu Apr 24 23:02:00 EDT 2025 Fri Feb 21 02:38:51 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | 2022. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c540t-110746137b4058947765b99dc302bea06fc2edcd2195d24faa50dd36214f88333 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41598-022-25231-0 |
PMID | 36450882 |
PQID | 2742909967 |
PQPubID | 2041939 |
PageCount | 17 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_ae98d897ec024c5fa1de8752049e2308 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9712677 proquest_miscellaneous_2744667471 proquest_journals_2742909967 pubmed_primary_36450882 crossref_citationtrail_10_1038_s41598_022_25231_0 crossref_primary_10_1038_s41598_022_25231_0 springer_journals_10_1038_s41598_022_25231_0 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-11-30 |
PublicationDateYYYYMMDD | 2022-11-30 |
PublicationDate_xml | – month: 11 year: 2022 text: 2022-11-30 day: 30 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | Scientific reports |
PublicationTitleAbbrev | Sci Rep |
PublicationTitleAlternate | Sci Rep |
PublicationYear | 2022 |
Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
References | ZhongHZengGHeLOverexpression of the lncRNA AC012213.3 promotes proliferation, migration and invasion of breast cancer via RAD54B/PI3K/AKT axis and is associated with worse patient prognosisCancer Manag. Res.2021137213722310.2147/cmar.S322195345570388453444 HuangZLiJChenJChenDConstruction of prognostic risk model of 5-methylcytosine-related long non-coding RNAs and evaluation of the characteristics of tumor-infiltrating immune cells in breast cancerFront. Genet.2021121:CAS:528:DC%2BB38XjvFCrtL4%3D10.3389/fgene.2021.748279347774738585929 LiTLINC00702/miR-4652–3p/ZEB1 axis promotes the progression of malignant meningioma through activating Wnt/β-catenin pathwayBiomed. Pharmacother. Biomed. Pharmacother.20191131087181:CAS:528:DC%2BC1MXktlKhsr0%3D10.1016/j.biopha.2019.10871830849635 YuDWangXJinZLinc00702 inhibits cell growth and metastasis through regulating PTEN in colorectal cancerEur. Rev. Med. Pharmacol. Sci.202024362436321:STN:280:DC%2BB38zptFCitg%3D%3D10.26355/eurrev_202004_2082432329837 RebbeckTModification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeatAm. J. Hum. Genet.199964137113771:CAS:528:DyaK1MXlt1ajt78%3D10.1086/302366102052681377873 CollinsLAndrogen receptor expression in breast cancer in relation to molecular phenotype: Results from the Nurses' Health StudyMod. Pathol.20112492493110.1038/modpathol.2011.54215522123128675 JahanNJonesCRahmanRAndrogen receptor expression in breast cancer: Implications on prognosis and treatment, a brief reviewMol. Cell. Endocrinol.20215311:CAS:528:DC%2BB3MXhtFCmsr7F10.1016/j.mce.2021.11132434000352 CochraneDRole of the androgen receptor in breast cancer and preclinical analysis of enzalutamideBreast Cancer Res. BCR201416R71:CAS:528:DC%2BC2MXivFGjsb0%3D10.1186/bcr359924451109 KanehisaMFurumichiMSatoYIshiguro-WatanabeMTanabeMKEGG: Integrating viruses and cellular organismsNucleic Acids Res.202149D545D5511:CAS:528:DC%2BB3MXntlejsLw%3D10.1093/nar/gkaa97033125081 BalicMThomssenCWürstleinRGnantMHarbeckNSGallenVSt. Gallen/Vienna 2019: A brief summary of the consensus discussion on the optimal primary breast cancer treatmentBreast Care (Basel, Switzerland)20191410311010.1159/00049993131798382 YaoMLINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progressionCell Death Dis.2020116381:CAS:528:DC%2BB3cXhs1ygtrjI10.1038/s41419-020-02856-5328013007429955 WangXZhangJLiuXWeiBZhanLLong noncoding RNAs in endometriosis: Biological functions, expressions, and mechanismsJ. Cell. Physiol.20212366141:CAS:528:DC%2BB3cXhtFSgsbbK10.1002/jcp.2984732506425 YaoYIntegrated analysis of co-expression and ceRNA network identifies five lncRNAs as prognostic markers for breast cancerJ. Cell Mol. Med.201923841084191:CAS:528:DC%2BC1MXitFOrs7zM10.1111/jcmm.14721316130586850943 GianniLNeoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohortLancet Oncol.2014156406471:CAS:528:DC%2BC2cXkslWiu78%3D10.1016/s1470-2045(14)70080-424657003 ShuaiCYangXPanHHanWEstrogen receptor downregulates expression of PD-1/PD-L1 and infiltration of CD8 T cells by inhibiting IL-17 signaling transduction in breast cancerFront. Oncol.20201010.3389/fonc.2020.582863331022397545792 NascimentoGMolecular characterization of Koolen De Vries syndrome in two girls with idiopathic intellectual disability from central BrazilMol. Syndromol.201781551601:CAS:528:DC%2BC2sXotVOjur4%3D10.1159/000456910285884375448449 DaiHHIF1α regulates IL17 signaling pathway influencing sensitivity of taxane-based chemotherapy for breast cancerFront. Cell Dev. Biol.2021910.3389/fcell.2021.729965345951778476907 Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.70, 313. https://doi.org/10.3322/caac.21609 (2020). HuangGZhouJChenJLiuGIdentification of pyroptosis related subtypes and tumor microenvironment infiltration characteristics in breast cancerSci. Rep.202212106402022NatSR..1210640H1:CAS:528:DC%2BB38Xhslajs7jP10.1038/s41598-022-14897-1357391829226023 NewmanARobust enumeration of cell subsets from tissue expression profilesNat. Methods2015124534571:CAS:528:DC%2BC2MXlsVOgu7Y%3D10.1038/nmeth.3337258228004739640 YamaguchiMAndrogens enhance the ability of intratumoral macrophages to promote breast cancer progressionOncol. Rep.202110.3892/or.2021.813934278480 NaderiAHughes-DaviesLA functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancerNeoplasia (New York, NY)2008105425481:CAS:528:DC%2BD1cXoslWgtb4%3D10.1593/neo.08274 YuZLong non-coding RNA COL4A2-AS1 facilitates cell proliferation and glycolysis of colorectal cancer cells via miR-20b-5p/hypoxia inducible factor 1 alpha subunit axisBioengineered202112625162631:CAS:528:DC%2BB3MXhvFKksr7F10.1080/21655979.2021.1969833344774768806750 ChenWIdentification of a tumor microenvironment-related gene signature indicative of disease prognosis and treatment response in colon cancerOxid. Med. Cell. Longev.2021202162902611:CAS:528:DC%2BB38XjvFKnu70%3D10.1155/2021/6290261344976818420973 BarecheYUnraveling triple-negative breast cancer tumor microenvironment heterogeneity: Towards an optimized treatment approachJ. Natl Cancer Inst.20201127087191:CAS:528:DC%2BB3cXis1CjsLfF10.1093/jnci/djz20831665482 AnestisAZoiIPapavassiliouAKaramouzisMAndrogen receptor in breast cancer-clinical and preclinical research insightsMolecules (Basel, Switzerland).202010.3390/molecules25020358319522727024330 DarHAssessment of 25-year survival of women with estrogen receptor-positive/ERBB2-negative breast cancer treated with and without tamoxifen therapy: A secondary analysis of data from the stockholm tamoxifen randomized clinical trialJAMA Netw. Open2021410.1001/jamanetworkopen.2021.14904341909958246315 BiFChenYYangQSignificance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancerCancer Cell Int.2020203731:CAS:528:DC%2BB3cXhsFGmtr%2FF10.1186/s12935-020-01472-9327741677405355 SubramanianAGene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProc. Natl. Acad. Sci. U.S.A.200510215545155501:CAS:528:DC%2BD2MXht1ShtrnO10.1073/pnas.0506580102161995171239896 CollinaFHOTAIRLncRNA up-regulation is strongly related with lymph nodes metastasis and LAR subtype of Triple Negative Breast CancerJ. Cancer201910201820241:CAS:528:DC%2BB3cXjslGitbs%3D10.7150/jca.29670312055626548158 PanH20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 yearsN. Engl. J. Med.20173771836184610.1056/NEJMoa1701830291174985734609 ShiYYangFHuangDGuanXAndrogen blockade based clinical trials landscape in triple negative breast cancerBiochim. Biophys. Acta. Rev. Cancer201818702832901:CAS:528:DC%2BC1cXhtFGjsbvL10.1016/j.bbcan.2018.05.00429807045 SchmidtKTargeting the oncogenic long non-coding RNA SLNCR1 by blocking its sequence-specific binding to the androgen receptorCell Rep.202030541554.e5451:CAS:528:DC%2BB3cXotFelur4%3D10.1016/j.celrep.2019.12.011319404957067293 KramerIBreast cancer polygenic risk score and contralateral breast cancer riskAm. J. Hum. Genet.20201078378481:CAS:528:DC%2BB3cXitVWrurzJ10.1016/j.ajhg.2020.09.001330222217675034 LiuCWangXGenchevGLuHMulti-omics facilitated variable selection in Cox-regression model for cancer prognosis predictionMethods (San Diego, Calif.)20171241001071:CAS:528:DC%2BC2sXhtF2qu7nL10.1016/j.ymeth.2017.06.01028627406 ZhouWPangYYaoYQiaoHDevelopment of a Ten-lncRNA signature prognostic model for breast cancer survival: A study with the TCGA databaseAnal. Cell. Pathol. (Amst.)2020202068270571:CAS:528:DC%2BB3cXitlWru73N10.1155/2020/682705732908814 De AmicisFAndrogen receptor overexpression induces tamoxifen resistance in human breast cancer cellsBreast Cancer Res. Treat.20101211111:CAS:528:DC%2BC3cXkvVymtL0%3D10.1007/s10549-009-0436-819533338 McNamaraKSasanoHAndrogen and breast cancer: An updateCurr. Opin. Endocrinol. Diabetes Obes.2016232492561:CAS:528:DC%2BC28XmvFCisLc%3D10.1097/med.000000000000025126945136 YangFAn androgen receptor negatively induced long non-coding RNA ARNILA binding to miR-204 promotes the invasion and metastasis of triple-negative breast cancerCell Death Differ.201825220922201:CAS:528:DC%2BC1cXhtVGgu7%2FL10.1038/s41418-018-0123-6298445706261952 LeTThe ADAM9/UBN2/AKR1C3 axis promotes resistance to androgen-deprivation in prostate cancerAm. J. Cancer Res.2022121761971:CAS:528:DC%2BB38Xht1KlurbO351410128822277 W Chen (25231_CR23) 2021; 2021 Z Yu (25231_CR29) 2021; 12 A Newman (25231_CR21) 2015; 12 L Gianni (25231_CR2) 2014; 15 H Pan (25231_CR3) 2017; 377 Y Shi (25231_CR12) 2018; 1870 A Subramanian (25231_CR20) 2005; 102 K Schmidt (25231_CR15) 2020; 30 C Liu (25231_CR17) 2017; 124 G Nascimento (25231_CR27) 2017; 8 25231_CR1 D Cochrane (25231_CR10) 2014; 16 F Collina (25231_CR34) 2019; 10 A Naderi (25231_CR11) 2008; 10 M Yamaguchi (25231_CR40) 2021 T Li (25231_CR33) 2019; 113 T Rebbeck (25231_CR13) 1999; 64 C Shuai (25231_CR37) 2020; 10 L Collins (25231_CR6) 2011; 24 X Wang (25231_CR14) 2021; 236 D Yu (25231_CR32) 2020; 24 F Yang (25231_CR35) 2018; 25 Z Huang (25231_CR31) 2021; 12 I Kramer (25231_CR24) 2020; 107 A Anestis (25231_CR25) 2020 H Zhong (25231_CR26) 2021; 13 H Dar (25231_CR4) 2021; 4 K McNamara (25231_CR7) 2016; 23 M Balic (25231_CR5) 2019; 14 F De Amicis (25231_CR9) 2010; 121 N Jahan (25231_CR8) 2021; 531 G Huang (25231_CR18) 2022; 12 F Bi (25231_CR22) 2020; 20 Y Yao (25231_CR30) 2019; 23 M Kanehisa (25231_CR19) 2021; 49 Y Bareche (25231_CR39) 2020; 112 T Le (25231_CR38) 2022; 12 H Dai (25231_CR36) 2021; 9 W Zhou (25231_CR28) 2020; 2020 M Yao (25231_CR16) 2020; 11 |
References_xml | – reference: NaderiAHughes-DaviesLA functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancerNeoplasia (New York, NY)2008105425481:CAS:528:DC%2BD1cXoslWgtb4%3D10.1593/neo.08274 – reference: LiuCWangXGenchevGLuHMulti-omics facilitated variable selection in Cox-regression model for cancer prognosis predictionMethods (San Diego, Calif.)20171241001071:CAS:528:DC%2BC2sXhtF2qu7nL10.1016/j.ymeth.2017.06.01028627406 – reference: LeTThe ADAM9/UBN2/AKR1C3 axis promotes resistance to androgen-deprivation in prostate cancerAm. J. Cancer Res.2022121761971:CAS:528:DC%2BB38Xht1KlurbO351410128822277 – reference: AnestisAZoiIPapavassiliouAKaramouzisMAndrogen receptor in breast cancer-clinical and preclinical research insightsMolecules (Basel, Switzerland).202010.3390/molecules25020358319522727024330 – reference: GianniLNeoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohortLancet Oncol.2014156406471:CAS:528:DC%2BC2cXkslWiu78%3D10.1016/s1470-2045(14)70080-424657003 – reference: McNamaraKSasanoHAndrogen and breast cancer: An updateCurr. Opin. Endocrinol. Diabetes Obes.2016232492561:CAS:528:DC%2BC28XmvFCisLc%3D10.1097/med.000000000000025126945136 – reference: ZhouWPangYYaoYQiaoHDevelopment of a Ten-lncRNA signature prognostic model for breast cancer survival: A study with the TCGA databaseAnal. Cell. Pathol. (Amst.)2020202068270571:CAS:528:DC%2BB3cXitlWru73N10.1155/2020/682705732908814 – reference: DaiHHIF1α regulates IL17 signaling pathway influencing sensitivity of taxane-based chemotherapy for breast cancerFront. Cell Dev. Biol.2021910.3389/fcell.2021.729965345951778476907 – reference: CochraneDRole of the androgen receptor in breast cancer and preclinical analysis of enzalutamideBreast Cancer Res. BCR201416R71:CAS:528:DC%2BC2MXivFGjsb0%3D10.1186/bcr359924451109 – reference: BiFChenYYangQSignificance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancerCancer Cell Int.2020203731:CAS:528:DC%2BB3cXhsFGmtr%2FF10.1186/s12935-020-01472-9327741677405355 – reference: RebbeckTModification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeatAm. J. Hum. Genet.199964137113771:CAS:528:DyaK1MXlt1ajt78%3D10.1086/302366102052681377873 – reference: NascimentoGMolecular characterization of Koolen De Vries syndrome in two girls with idiopathic intellectual disability from central BrazilMol. Syndromol.201781551601:CAS:528:DC%2BC2sXotVOjur4%3D10.1159/000456910285884375448449 – reference: ChenWIdentification of a tumor microenvironment-related gene signature indicative of disease prognosis and treatment response in colon cancerOxid. Med. Cell. Longev.2021202162902611:CAS:528:DC%2BB38XjvFKnu70%3D10.1155/2021/6290261344976818420973 – reference: LiTLINC00702/miR-4652–3p/ZEB1 axis promotes the progression of malignant meningioma through activating Wnt/β-catenin pathwayBiomed. Pharmacother. Biomed. Pharmacother.20191131087181:CAS:528:DC%2BC1MXktlKhsr0%3D10.1016/j.biopha.2019.10871830849635 – reference: CollinaFHOTAIRLncRNA up-regulation is strongly related with lymph nodes metastasis and LAR subtype of Triple Negative Breast CancerJ. Cancer201910201820241:CAS:528:DC%2BB3cXjslGitbs%3D10.7150/jca.29670312055626548158 – reference: PanH20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 yearsN. Engl. J. Med.20173771836184610.1056/NEJMoa1701830291174985734609 – reference: BarecheYUnraveling triple-negative breast cancer tumor microenvironment heterogeneity: Towards an optimized treatment approachJ. Natl Cancer Inst.20201127087191:CAS:528:DC%2BB3cXis1CjsLfF10.1093/jnci/djz20831665482 – reference: WangXZhangJLiuXWeiBZhanLLong noncoding RNAs in endometriosis: Biological functions, expressions, and mechanismsJ. Cell. Physiol.20212366141:CAS:528:DC%2BB3cXhtFSgsbbK10.1002/jcp.2984732506425 – reference: CollinsLAndrogen receptor expression in breast cancer in relation to molecular phenotype: Results from the Nurses' Health StudyMod. Pathol.20112492493110.1038/modpathol.2011.54215522123128675 – reference: YamaguchiMAndrogens enhance the ability of intratumoral macrophages to promote breast cancer progressionOncol. Rep.202110.3892/or.2021.813934278480 – reference: ZhongHZengGHeLOverexpression of the lncRNA AC012213.3 promotes proliferation, migration and invasion of breast cancer via RAD54B/PI3K/AKT axis and is associated with worse patient prognosisCancer Manag. Res.2021137213722310.2147/cmar.S322195345570388453444 – reference: YuZLong non-coding RNA COL4A2-AS1 facilitates cell proliferation and glycolysis of colorectal cancer cells via miR-20b-5p/hypoxia inducible factor 1 alpha subunit axisBioengineered202112625162631:CAS:528:DC%2BB3MXhvFKksr7F10.1080/21655979.2021.1969833344774768806750 – reference: YaoMLINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progressionCell Death Dis.2020116381:CAS:528:DC%2BB3cXhs1ygtrjI10.1038/s41419-020-02856-5328013007429955 – reference: De AmicisFAndrogen receptor overexpression induces tamoxifen resistance in human breast cancer cellsBreast Cancer Res. Treat.20101211111:CAS:528:DC%2BC3cXkvVymtL0%3D10.1007/s10549-009-0436-819533338 – reference: ShiYYangFHuangDGuanXAndrogen blockade based clinical trials landscape in triple negative breast cancerBiochim. Biophys. Acta. Rev. Cancer201818702832901:CAS:528:DC%2BC1cXhtFGjsbvL10.1016/j.bbcan.2018.05.00429807045 – reference: DarHAssessment of 25-year survival of women with estrogen receptor-positive/ERBB2-negative breast cancer treated with and without tamoxifen therapy: A secondary analysis of data from the stockholm tamoxifen randomized clinical trialJAMA Netw. Open2021410.1001/jamanetworkopen.2021.14904341909958246315 – reference: JahanNJonesCRahmanRAndrogen receptor expression in breast cancer: Implications on prognosis and treatment, a brief reviewMol. Cell. Endocrinol.20215311:CAS:528:DC%2BB3MXhtFCmsr7F10.1016/j.mce.2021.11132434000352 – reference: YuDWangXJinZLinc00702 inhibits cell growth and metastasis through regulating PTEN in colorectal cancerEur. Rev. Med. Pharmacol. Sci.202024362436321:STN:280:DC%2BB38zptFCitg%3D%3D10.26355/eurrev_202004_2082432329837 – reference: HuangGZhouJChenJLiuGIdentification of pyroptosis related subtypes and tumor microenvironment infiltration characteristics in breast cancerSci. Rep.202212106402022NatSR..1210640H1:CAS:528:DC%2BB38Xhslajs7jP10.1038/s41598-022-14897-1357391829226023 – reference: Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.70, 313. https://doi.org/10.3322/caac.21609 (2020). – reference: HuangZLiJChenJChenDConstruction of prognostic risk model of 5-methylcytosine-related long non-coding RNAs and evaluation of the characteristics of tumor-infiltrating immune cells in breast cancerFront. Genet.2021121:CAS:528:DC%2BB38XjvFCrtL4%3D10.3389/fgene.2021.748279347774738585929 – reference: KanehisaMFurumichiMSatoYIshiguro-WatanabeMTanabeMKEGG: Integrating viruses and cellular organismsNucleic Acids Res.202149D545D5511:CAS:528:DC%2BB3MXntlejsLw%3D10.1093/nar/gkaa97033125081 – reference: YaoYIntegrated analysis of co-expression and ceRNA network identifies five lncRNAs as prognostic markers for breast cancerJ. Cell Mol. Med.201923841084191:CAS:528:DC%2BC1MXitFOrs7zM10.1111/jcmm.14721316130586850943 – reference: BalicMThomssenCWürstleinRGnantMHarbeckNSGallenVSt. Gallen/Vienna 2019: A brief summary of the consensus discussion on the optimal primary breast cancer treatmentBreast Care (Basel, Switzerland)20191410311010.1159/00049993131798382 – reference: KramerIBreast cancer polygenic risk score and contralateral breast cancer riskAm. J. Hum. Genet.20201078378481:CAS:528:DC%2BB3cXitVWrurzJ10.1016/j.ajhg.2020.09.001330222217675034 – reference: ShuaiCYangXPanHHanWEstrogen receptor downregulates expression of PD-1/PD-L1 and infiltration of CD8 T cells by inhibiting IL-17 signaling transduction in breast cancerFront. Oncol.20201010.3389/fonc.2020.582863331022397545792 – reference: SchmidtKTargeting the oncogenic long non-coding RNA SLNCR1 by blocking its sequence-specific binding to the androgen receptorCell Rep.202030541554.e5451:CAS:528:DC%2BB3cXotFelur4%3D10.1016/j.celrep.2019.12.011319404957067293 – reference: SubramanianAGene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProc. Natl. Acad. Sci. U.S.A.200510215545155501:CAS:528:DC%2BD2MXht1ShtrnO10.1073/pnas.0506580102161995171239896 – reference: NewmanARobust enumeration of cell subsets from tissue expression profilesNat. Methods2015124534571:CAS:528:DC%2BC2MXlsVOgu7Y%3D10.1038/nmeth.3337258228004739640 – reference: YangFAn androgen receptor negatively induced long non-coding RNA ARNILA binding to miR-204 promotes the invasion and metastasis of triple-negative breast cancerCell Death Differ.201825220922201:CAS:528:DC%2BC1cXhtVGgu7%2FL10.1038/s41418-018-0123-6298445706261952 – volume: 49 start-page: D545 year: 2021 ident: 25231_CR19 publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkaa970 – volume: 20 start-page: 373 year: 2020 ident: 25231_CR22 publication-title: Cancer Cell Int. doi: 10.1186/s12935-020-01472-9 – year: 2021 ident: 25231_CR40 publication-title: Oncol. Rep. doi: 10.3892/or.2021.8139 – volume: 12 start-page: 453 year: 2015 ident: 25231_CR21 publication-title: Nat. Methods doi: 10.1038/nmeth.3337 – volume: 12 year: 2021 ident: 25231_CR31 publication-title: Front. Genet. doi: 10.3389/fgene.2021.748279 – volume: 1870 start-page: 283 year: 2018 ident: 25231_CR12 publication-title: Biochim. Biophys. Acta. Rev. Cancer doi: 10.1016/j.bbcan.2018.05.004 – volume: 30 start-page: 541 year: 2020 ident: 25231_CR15 publication-title: Cell Rep. doi: 10.1016/j.celrep.2019.12.011 – volume: 12 start-page: 6251 year: 2021 ident: 25231_CR29 publication-title: Bioengineered doi: 10.1080/21655979.2021.1969833 – volume: 4 year: 2021 ident: 25231_CR4 publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2021.14904 – volume: 64 start-page: 1371 year: 1999 ident: 25231_CR13 publication-title: Am. J. Hum. Genet. doi: 10.1086/302366 – volume: 236 start-page: 6 year: 2021 ident: 25231_CR14 publication-title: J. Cell. Physiol. doi: 10.1002/jcp.29847 – volume: 12 start-page: 176 year: 2022 ident: 25231_CR38 publication-title: Am. J. Cancer Res. – volume: 377 start-page: 1836 year: 2017 ident: 25231_CR3 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1701830 – volume: 23 start-page: 249 year: 2016 ident: 25231_CR7 publication-title: Curr. Opin. Endocrinol. Diabetes Obes. doi: 10.1097/med.0000000000000251 – volume: 24 start-page: 3624 year: 2020 ident: 25231_CR32 publication-title: Eur. Rev. Med. Pharmacol. Sci. doi: 10.26355/eurrev_202004_20824 – volume: 10 start-page: 2018 year: 2019 ident: 25231_CR34 publication-title: J. Cancer doi: 10.7150/jca.29670 – volume: 12 start-page: 10640 year: 2022 ident: 25231_CR18 publication-title: Sci. Rep. doi: 10.1038/s41598-022-14897-1 – volume: 25 start-page: 2209 year: 2018 ident: 25231_CR35 publication-title: Cell Death Differ. doi: 10.1038/s41418-018-0123-6 – volume: 2021 start-page: 6290261 year: 2021 ident: 25231_CR23 publication-title: Oxid. Med. Cell. Longev. doi: 10.1155/2021/6290261 – volume: 107 start-page: 837 year: 2020 ident: 25231_CR24 publication-title: Am. J. Hum. Genet. doi: 10.1016/j.ajhg.2020.09.001 – volume: 113 start-page: 108718 year: 2019 ident: 25231_CR33 publication-title: Biomed. Pharmacother. Biomed. Pharmacother. doi: 10.1016/j.biopha.2019.108718 – ident: 25231_CR1 doi: 10.3322/caac.21609 – volume: 2020 start-page: 6827057 year: 2020 ident: 25231_CR28 publication-title: Anal. Cell. Pathol. (Amst.) doi: 10.1155/2020/6827057 – volume: 8 start-page: 155 year: 2017 ident: 25231_CR27 publication-title: Mol. Syndromol. doi: 10.1159/000456910 – volume: 13 start-page: 7213 year: 2021 ident: 25231_CR26 publication-title: Cancer Manag. Res. doi: 10.2147/cmar.S322195 – volume: 121 start-page: 1 year: 2010 ident: 25231_CR9 publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-009-0436-8 – volume: 16 start-page: R7 year: 2014 ident: 25231_CR10 publication-title: Breast Cancer Res. BCR doi: 10.1186/bcr3599 – volume: 102 start-page: 15545 year: 2005 ident: 25231_CR20 publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.0506580102 – year: 2020 ident: 25231_CR25 publication-title: Molecules (Basel, Switzerland). doi: 10.3390/molecules25020358 – volume: 23 start-page: 8410 year: 2019 ident: 25231_CR30 publication-title: J. Cell Mol. Med. doi: 10.1111/jcmm.14721 – volume: 9 year: 2021 ident: 25231_CR36 publication-title: Front. Cell Dev. Biol. doi: 10.3389/fcell.2021.729965 – volume: 531 year: 2021 ident: 25231_CR8 publication-title: Mol. Cell. Endocrinol. doi: 10.1016/j.mce.2021.111324 – volume: 15 start-page: 640 year: 2014 ident: 25231_CR2 publication-title: Lancet Oncol. doi: 10.1016/s1470-2045(14)70080-4 – volume: 112 start-page: 708 year: 2020 ident: 25231_CR39 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djz208 – volume: 14 start-page: 103 year: 2019 ident: 25231_CR5 publication-title: Breast Care (Basel, Switzerland) doi: 10.1159/000499931 – volume: 10 year: 2020 ident: 25231_CR37 publication-title: Front. Oncol. doi: 10.3389/fonc.2020.582863 – volume: 11 start-page: 638 year: 2020 ident: 25231_CR16 publication-title: Cell Death Dis. doi: 10.1038/s41419-020-02856-5 – volume: 10 start-page: 542 year: 2008 ident: 25231_CR11 publication-title: Neoplasia (New York, NY) doi: 10.1593/neo.08274 – volume: 124 start-page: 100 year: 2017 ident: 25231_CR17 publication-title: Methods (San Diego, Calif.) doi: 10.1016/j.ymeth.2017.06.010 – volume: 24 start-page: 924 year: 2011 ident: 25231_CR6 publication-title: Mod. Pathol. doi: 10.1038/modpathol.2011.54 |
SSID | ssj0000529419 |
Score | 2.4285417 |
Snippet | Androgen receptor (AR) is strong association with breast cancer (BRCA). We aimed to investigate the effect of the androgen receptor signaling pathway-related... Abstract Androgen receptor (AR) is strong association with breast cancer (BRCA). We aimed to investigate the effect of the androgen receptor signaling... |
SourceID | doaj pubmedcentral proquest pubmed crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 20631 |
SubjectTerms | 692/4028 692/499 Androgen receptors Androgens Breast cancer Breast Neoplasms - genetics CD4 antigen Cluster analysis Female Gene set enrichment analysis Humanities and Social Sciences Humans Immunosuppressive agents Infiltration Lymphocytes B Lymphocytes T Macrophages Metastases multidisciplinary Nomograms Non-coding RNA Prognosis Receptors, Androgen - genetics Regression analysis Risk groups RNA, Long Noncoding - genetics Science Science (multidisciplinary) Signal Transduction Tumor microenvironment Tumor Microenvironment - genetics Tumors |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlUOiltE0fTpOiQm-tiS3LknVMQkIINIfQQG5ClkbUsNgh3qXk33dG9m6zfV56XWm9Ws2M5xtm5hvGPjhwEHV0uYFK5lLXMm9EQMNro241CFFKak7-fKnOr-XFTX3zYNQX1YRN9MDTxR06ME1ojAaP3sTX0ZUBEGMLRLaA8Dm1-aLPexBMTazewsjSzF0yRdUcjuipqJsMYy-BwRfG0FueKBH2_w5l_los-VPGNDmis2fs6Ywg-dF08ufsEfQv2ONppuT9LltdDQvgQ-SOqAhQPTi-0-AWQ2tOtRqO2s85zSH-5u7z1MkCgS96f3V5NPKu5wgIORVt9cPYjfQQ3lELCeBa7BYzyS49v6Vy9iX3pDZ3L9n12emXk_N8nq2Qe8Roy5zCPomuXLeSBgtKrVXdGhN8VYgWXKGiF_ifA77Q6iBkdK4uQkBvV8pI84mrV2ynH3p4w3jQRTQiFsFhdOMkQoaofaNiJUHWUcmMlet7tn4mHqf5FwubEuBVYyfZWJSNTbKxRcY-br5zO9Fu_HX3MYlvs5Mos9MHqEh2ViT7L0XK2P5a-Ha249FSItsgiFY6Y-83y2iBlFZxPQyrtEcqRcF9xl5PurI5CSV5KYjJmN7Soq2jbq_03dfE8m10KZTG3_201rcfx_rzVez9j6t4y54IMpTEcLnPdpZ3KzhA7LVs3yUz-w6EVSmV priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkL4k1KQUbiBlETx7HjEyqIqkKih4pKe7McPyDSKlk2u0L9951xvKmWR6-xkziZGc98nhch74w3PshgcuUrnnNZ87xhDgSvDbKVnrGSY3Lyt3Nxdsm_LupFOnAbU1jlbk-MG7UbLJ6RH6NLUYE5I-TH1a8cu0ahdzW10LhL7mHpMuRquZDzGQt6sXipUq5MUTXHI-grzCkDBMYAggGS3tNHsWz_v2zNv0Mm__CbRnV0-og8THYkPZkI_5jc8f0Tcn_qLHn1lGwvhqWnQ6AGCxIAk1DY2fwKADbFiA2DSegUuxH_Nld5zGfxji57e3F-MtKup2AWUgzd6oexG_EhtMNEEg9joVumUrv4_BaD2jfUIvOsn5HL0y_fP5_lqcNCbsFS2-QI_jgodNlybC_IpRR1q5SzVcFabwoRLINvdrCt1Y7xYExdOAc6r-QBuxRXz8lBP_T-JaFOFkGxUDgDGMdwMByCtI0IFfe8DoJnpNz9Z21T-XHsgrHU0Q1eNXqijQba6EgbXWTk_XzPaiq-cevsT0i-eSYWzo4XhvUPneRQG68a1yjpLRgntg6mdB4gGwOg5AGNNRk52hFfJ2ke9Q3vZeTtPAxyiM4V0_thG-dwIRDiZ-TFxCvzStDVi1AmI3KPi_aWuj_Sdz9jrW8lSyYkvPfDjt9ulvX_X3F4-1e8Ig8YikCsYHlEDjbrrX8NttWmfRMF6BrnoiFh priority: 102 providerName: ProQuest – databaseName: Springer Nature HAS Fully OA dbid: AAJSJ link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB6VVkhcUMuroS0yEjeISBwnjo8LoqpWoodCpd4sJ7Yh0iqpNrtC_ffMOA-0UJC4rp2sk5mx58vMfAPwxjjjvPQmVi4TsZC5iEtu0fAqLyvpOE8FFSd_viwursXyJr_ZAz7VwoSk_UBpGbbpKTvsfY8HDRWDIXTiiJ0QAj-AA6JqR90-WCyWX5bzlxWKXYlUjRUySVbec_HOKRTI-u_zMP9MlPwtWhoOofNDeDx6j2wxrPcI9lz7BB4O_STvnsL2qls51nlmiIYAVYPhfuZuEVYzytMwVHrOqAfxD3MXhyoWZ9mqra8uFz1rWobOIKOErbbrm55uwhoqH3E45pvVSLBL968olX3DalKZ9TO4Pv_09eNFPPZViGv0zzYxQT6Bx7isBDUVFFIWeaWUrbOEV84kha85PrPFzSy3XHhj8sRaPOlS4ak3cfYc9tuudcfArEy84j6xBpGNEegueFmXhc-EE7kvRATp9J51PZKOU--LlQ7B76zUg2w0ykYH2egkgrfzNbcD5cY_Z38g8c0ziS47_NCtv-lRfbRxqrSlkq5Gl6TOvUmtQ6DGER45xGBlBKeT8PVow72mILZCB7qQEbyeh9H6KKRiWtdtwxxRFATsI3gx6Mq8EgrwEoCJQO5o0c5Sd0fa5ntg-FYy5YXE_3036duvZf39Vbz8v-kn8IiTSQQey1PY36y37gw9rE31ajSpn39_IFo priority: 102 providerName: Springer Nature |
Title | Role of androgen receptor signaling pathway-related lncRNAs in the prognosis and immune infiltration of breast cancer |
URI | https://link.springer.com/article/10.1038/s41598-022-25231-0 https://www.ncbi.nlm.nih.gov/pubmed/36450882 https://www.proquest.com/docview/2742909967 https://www.proquest.com/docview/2744667471 https://pubmed.ncbi.nlm.nih.gov/PMC9712677 https://doaj.org/article/ae98d897ec024c5fa1de8752049e2308 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9NAEB_uA8EX8dvoWVbwTaPJZpNNHkR65Y6jcEWqhb6FTXb3DITk7Afa_96ZTVqpVp98KmQ36XZnJjO_zs5vAF4ro4yVVvmZiYQvZCz8lGs0vMLKQhrOQ0HFydeT5GomxvN4fgTbdkf9Bi4PQjvqJzVb1O9-fNt8RIP_0JWMp--X6ISoUAxhFUdchfD4GE7RM0nqaHDdh_sd1zfPRJj1tTOHb93zT47G_1Ds-ecRyt_yqM49Xd6He31cyYadIjyAI9M8hDtdp8nNI1hP29qw1jJFBAWoNAzfdOYWATejExyKitIZdSf-rja-q28xmtVNOZ0Ml6xqGIaJjI5yNe2yWtJDWEWFJQbHbFX31Lv0_IIOua9YScq0eAyzy4svoyu_77jglxi5rXwCgwIdvCwEtRsUUiZxkWW6jAJeGBUktuT4mzW-5mLNhVUqDrRGHxgKS12Loydw0rSNeQZMy8Bm3AZaIeZRAgMJK8s0sZEwIraJ8CDc7nNe9nTk1BWjzl1aPErzTjY5yiZ3sskDD97s7rntyDj-OfucxLebSUTa7kK7uMl7u8yVyVKdZtKUGKyUsVWhNgjhOAIng-gs9eBsK_x8q5w5pbczDK0T6cGr3TDaJSVbVGPatZsjkoQgvwdPO13ZrYRSvwRtPJB7WrS31P2RpvrquL8zGfJE4ve-3erbr2X9fSue_4-teAF3ORmK4708g5PVYm1eYkS2KgZwLOdyAKfD4fjzGD_PLyafpnh1lIwG7l-OgTPEnxFYNzM |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGEIIXxHUEBhgJniBa4jhx8oDQuEwd2_owbVLfjOMLRKqS0rSa-qf4jZzjJJ3KZW97rV3X9bn4fD43Ql4rq6wTToWFTXjIRcrDnBkQvNKJUljGYo7JySfjbHTOv07SyRb5NeTCYFjloBO9ojaNxjfyPXQpFmDOZOLD7GeIXaPQuzq00OjY4siuLgCyte8PPwN93zB28OXs0yjsuwqEGqyTRYiAh8MlJkqOLfW4EFlaFoXRScRKq6LMaWaNNiDKqWHcKZVGxoCej7nDzrwJrHuD3ISLN0KwJyZi_aaDXjMeF31uTpTkey3cj5jDBoiPAeQD5L5x__k2Af-ybf8O0fzDT-uvv4N75G5vt9L9jtHuky1bPyC3uk6Wq4dkedpMLW0cVVgAAZiSgia1MwD0FCNEFCa9U-x-fKFWoc-fsYZOa3063m9pVVMwQymGitVNW7W4CK0wccXCmKumfWlfXL_EIPoF1cis80fk_FrO_jHZrpvaPiHUiMgVzEVGAaZSHAwVJ3SeuYRbnrqMByQezlnqvtw5dt2YSu92T3LZ0UYCbaSnjYwC8nb9nVlX7OPK2R-RfOuZWKjbf9DMv8te7qWyRW7yQlgNxpBOnYqNBYjIAJhZQH95QHYH4stee7TyktcD8mo9DHKPzhxV22bp5_AswyeFgOx0vLLeCbqWEToFRGxw0cZWN0fq6oevLV6ImGUCfvfdwG-X2_r_UTy9-l-8JLdHZyfH8vhwfPSM3GEoDr565i7ZXsyX9jnYdYvyhRcmSr5dt_T-BrS1XGg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4anUC8IO4EBhgJniBq4jhx8oDQxjZtDKqpYtLeguMLVKqS0rSa-tf4dZyTS6dy2dtea9d1fS4-n88N4LWyyjrplJ_ZSPhCxsJPuUHBK5wspOU8FJSc_GWUHJ2JT-fx-Rb86nNhKKyy14mNojaVpjfyIbkUMzRnEjl0XVjE6f7hh9lPnzpIkae1b6fRssiJXV0gfKvfH-8jrd9wfnjw9eOR33UY8DVaKgufwI_AC00WgtrrCSmTuMgyo6OAF1YFidPcGm1QrGPDhVMqDoxBnR8KR116I1z3BmxLQkUD2N47GJ2O1y885EMTYdZl6gRROqzxtqSMNsR_HAEg4viN27BpGvAvS_fvgM0_vLbNZXh4F-50VizbbdnuHmzZ8j7cbPtarh7AclxNLascU1QOAVmUoV61M4T3jOJFFKXAM-qFfKFWfpNNYw2blno82q3ZpGRolDIKHCurelLTImxCaSwWx9xk2hX6pfULCqlfME2sO38IZ9dy-o9gUFalfQLMyMBl3AVGIcJSAs0WJ3WauEhYEbtEeBD255zrrvg59eCY5o0TPkrzljY50iZvaJMHHrxdf2fWlv64cvYekW89k8p2Nx9U8-95pwVyZbPUpJm0Gk0jHTsVGouAkSNMs4gFUw92euLnnS6p80vO9-DVehi1ALl2VGmrZTNHJAk9MHjwuOWV9U7I0UxAygO5wUUbW90cKSc_mkrjmQx5IvF33_X8drmt_x_F06v_xUu4hZKbfz4enTyD25ykoSmluQODxXxpn6ORtyhedNLE4Nt1C_BvILNiAw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+of+androgen+receptor+signaling+pathway-related+lncRNAs+in+the+prognosis+and+immune+infiltration+of+breast+cancer&rft.jtitle=Scientific+reports&rft.au=Guo+Huang&rft.au=Hong+Cao&rft.au=Guowen+Liu&rft.au=Juan+Chen&rft.date=2022-11-30&rft.pub=Nature+Portfolio&rft.eissn=2045-2322&rft.volume=12&rft.issue=1&rft.spage=1&rft.epage=17&rft_id=info:doi/10.1038%2Fs41598-022-25231-0&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_ae98d897ec024c5fa1de8752049e2308 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |